Industry’s shift towards large molecules and how to maintain balance

Executives from the largest companies in the industry discuss the increasing prevalence of biologics and the future focus for therapeutics at Pharma Integrates.

Speaking at a panel discussion titled ‘Size matters – out with the small molecules?’ during the Pharma Integrates conference, that took place in London earlier this week, Alastair Coupe, the senior director of Pharmaceutical Sciences at Pfizer, described one of his memories with the company, which marked the coming of the biologics ‘tsunami’.

Read the full article here

Industry’s shift towards large molecules and how to maintain balance